Nefazodone

Drug Profile

Nefazodone

Alternative Names: BMY 13754; Dutonin; MJ 13754; MS 13754; Nefadar; Serzone

Latest Information Update: 20 Feb 2015

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Menarini; Merck KGaA; Mitsubishi Pharma Corporation; Teva Pharmaceutical Industries
  • Class Antidepressants; Small molecules; Triazoles
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin 2 receptor antagonists; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Discontinued Panic disorder

Most Recent Events

  • 30 May 2013 Biomarkers information updated
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 29 Jun 2004 Discontinued - Phase-II for Depression in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top